A randomized, double-blind study of the efficacy of fleroxacin versus trimethoprim-sulfamethoxazole in men with culture-proven chancroid
| Autor: | Elizabeth Agoki, Allan R. Ronald, John Ombette, Pierre J. Plourde, Jackoniah O. Ndinya-Achola, L J D'Costa, L Slaney, Francis A. Plummer |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Sexually transmitted disease
Adult Male medicine.medical_specialty Fleroxacin Administration Oral urologic and male genital diseases Chancroid Double-Blind Method Oral administration Internal medicine Trimethoprim Sulfamethoxazole Drug Combination medicine Immunology and Allergy Humans Antibacterial agent biology business.industry Sulfamethoxazole Middle Aged bacterial infections and mycoses biology.organism_classification medicine.disease Trimethoprim female genital diseases and pregnancy complications Surgery Infectious Diseases business Haemophilus ducreyi medicine.drug Follow-Up Studies |
| Zdroj: | The Journal of infectious diseases. 165(5) |
| ISSN: | 0022-1899 |
| Popis: | Chancroid is linked to the spread of human immunodeficiency virus type 1 (HIV-1) in East Africa. Effective, easily administered therapy is a priority for the control of Haemophilus ducreyi. The efficacy of a single oral dose of fleroxacin, 400 mg, was compared to a 3-day oral course of trimethoprim-sulfamethoxazole (TMP-SMZ), 160/800 mg, twice daily for the treatment of chancroid in 98 HIV-1-seronegative men in Nairobi, Kenya. No differences were noted between the two groups with respect to demographic characteristics, sexual behavior, and clinical characteristics. Culture-proven failure occurred in 1 (3%) of 36 fleroxacin-treated patients and in 11 (30%) of 37 TMP-SMZ-treated patients (P = .005). Fleroxacin, as a single oral dose, is an effective treatment for culture-proven chancroid in patients who are HIV-1 seronegative. TMP-SMZ is no longer predictably effective due to the recent emergence of resistance to both sulfonamides and to trimethoprim. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|